Loading
Life sciences · Review
Quality in Sport · September 13, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Review.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background: Tirzepatide, as a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, has become one of the most effective pharmacological therapies used to treat obesity and metabolic disorders. Growing interest in its potential use among physically active individuals and the inclusion of tirzepatide markers in the World Anti-Doping Agency’s (WADA) monitoring program for 2026 highlight the need to reassess the significance of this substance in sports. Aim: The aim of this study was to update the available data on tirzepatide in the context of sports. Material and methods: A narrative review of the current literature on tirzepatide, incretin receptor agonists and their use in the context of sports was conducted. The analysis included clinical trials, systematic reviews, publications on body composition, metabolism, and exercise adaptation, as well as WADA regulatory documents. Results: Tirzepatide effectively reduces body weight and improves metabolic parameters. However, available evidence mainly concerns individuals with obesity or type 2 diabetes, rather than athletes. Changes in lean body mass during therapy may be relevant for physically active individuals, especially in sports requiring high strength and power. Although weight reduction could be beneficial in weight-class sports. Further studies are needed to assess the long-term impact of tirzepatide on athletic performance and to address the ethical issues associated with its use. Conclusions: Tirzepatide currently has no proven effect on enhancing athletic performance. However, its impact on body weight and body composition may be important for athletes. The inclusion of tirzepatide in WADA’s monitoring program highlights the need for further research into its potential misuse, its effects on muscle, and the long-term consequences of its utilization in the athletic population.